Thomasian Harry Jr. sold $606K of PGEN

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro

Precigen Inc. (PGEN) rose 11.62% to close at $5.38 on Monday for a second straight session. The gain followed the company’s late-month FDA approval granting six-year orphan drug exclusivity for Papzimeos to treat recurrent respiratory papillomatosis in the U.S., extending protection until Aug. 14, 2032, according to Precigen.